Towards optimizing the sequence of bevacizumab and nitrosoureas in recurrent malignant glioma.
about
Retrospective study of carmustine or lomustine with bevacizumab in recurrent glioblastoma patients who have failed prior bevacizumab.The future of high-grade glioma: Where we are and where are we going.Why post-progression survival and post-relapse survival are not appropriate measures of efficacy in cancer randomized clinical trials.A randomized phase II trial of standard dose bevacizumab versus low dose bevacizumab plus lomustine (CCNU) in adults with recurrent glioblastomaAddition of lomustine for bevacizumab-refractory recurrent glioblastoma.Progression-free and overall survival in patients with recurrent Glioblastoma multiforme treated with last-line bevacizumab versus bevacizumab/lomustine.
P2860
Towards optimizing the sequence of bevacizumab and nitrosoureas in recurrent malignant glioma.
description
2014 nî lūn-bûn
@nan
2014年の論文
@ja
2014年学术文章
@wuu
2014年学术文章
@zh-cn
2014年学术文章
@zh-hans
2014年学术文章
@zh-my
2014年学术文章
@zh-sg
2014年學術文章
@yue
2014年學術文章
@zh
2014年學術文章
@zh-hant
name
Towards optimizing the sequenc ...... in recurrent malignant glioma.
@en
Towards optimizing the sequenc ...... in recurrent malignant glioma.
@nl
type
label
Towards optimizing the sequenc ...... in recurrent malignant glioma.
@en
Towards optimizing the sequenc ...... in recurrent malignant glioma.
@nl
prefLabel
Towards optimizing the sequenc ...... in recurrent malignant glioma.
@en
Towards optimizing the sequenc ...... in recurrent malignant glioma.
@nl
P2093
P2860
P50
P1476
Towards optimizing the sequenc ...... in recurrent malignant glioma.
@en
P2093
Alexander Radbruch
Andreas Unterberg
Antje Wick
Benedikt Wiestler
Christine Jungk
Frank Winkler
Matthias Osswald
P2860
P2888
P356
10.1007/S11060-013-1356-3
P577
2014-01-24T00:00:00Z
P6179
1047573245